| preprint | Q580922 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1125955149 |
| P356 | DOI | 10.1101/2020.03.26.010322 |
| P932 | PMC publication ID | 7239077 |
| P698 | PubMed publication ID | 32511336 |
| P8299 | Semantic Scholar corpus ID | 214763496 |
| P50 | author | Jason S. McLellan | Q67209430 |
| Daniel Wrapp | Q87989047 | ||
| Joel Allen | Q88488050 | ||
| Max Crispin | Q38317988 | ||
| Yasunori Watanabe | Q63922335 | ||
| P2093 | author name string | Joel D Allen | |
| P2860 | cites work | Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion | Q84315378 |
| Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans | Q84316288 | ||
| Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein | Q87973551 | ||
| Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation | Q89108866 | ||
| Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses | Q89866691 | ||
| Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study | Q89916803 | ||
| Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers | Q90680433 | ||
| Vulnerabilities in coronavirus glycan shields despite extensive glycosylation | Q95933666 | ||
| Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus | Q27660330 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G | Q27704710 | ||
| Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers | Q28263063 | ||
| Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope | Q28263655 | ||
| Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin | Q28264707 | ||
| Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein | Q29306052 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design | Q30387829 | ||
| Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein | Q33529338 | ||
| The N-Glycome of Human Plasma | Q34104742 | ||
| Emerging principles for the therapeutic exploitation of glycosylation. | Q34395447 | ||
| Coronaviruses: an overview of their replication and pathogenesis. | Q34464697 | ||
| Coronavirus envelope (E) protein remains at the site of assembly | Q35998551 | ||
| Exploiting the defensive sugars of HIV-1 for drug and vaccine design | Q36802333 | ||
| Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding | Q37240035 | ||
| Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer | Q38290294 | ||
| Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. | Q40083207 | ||
| Variability, heritability and environmental determinants of human plasma N-glycome | Q46227174 | ||
| Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies. | Q52341903 | ||
| cisTEM, user-friendly software for single-particle image processing. | Q52669732 | ||
| Structural analysis of glycoproteins: building N-linked glycans with Coot. | Q54946742 | ||
| Proliferative growth of SARS coronavirus in Vero E6 cells | Q56766827 | ||
| The intracellular sites of early replication and budding of SARS-coronavirus | Q56877432 | ||
| Structure of the Lassa virus glycan shield provides a model for immunological resistance | Q56941600 | ||
| Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen | Q57010966 | ||
| Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization | Q58730221 | ||
| Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer | Q58747611 | ||
| The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template | Q64281085 | ||
| Exploitation of glycosylation in enveloped virus pathobiology | Q64359271 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| COVID-19 pandemic | Q81068910 | ||
| COVID-19 | Q84263196 | ||
| P577 | publication date | 2020-03-29 | |
| P1433 | published in | bioRxiv | Q19835482 |
| P1476 | title | Site-specific analysis of the SARS-CoV-2 glycan shield |
| Q99247023 | Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes |
| Q99418269 | Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition |
| Q96687815 | Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis |
| Q106626789 | Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM |
| Q94503955 | Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 |
| Q107349299 | Fluorescent Glycan Fingerprinting of SARS2 Spike Proteins |
| Q107341575 | Identification, Mapping and Relative Quantitation of SARS-CoV-2 Spike Glycopeptides by Mass-Retention Time Fingerprinting |
| Q96642693 | Landscape and Selection of Vaccine Epitopes in SARS-CoV-2 |
| Q108127425 | Landscape and selection of vaccine epitopes in SARS-CoV-2 |
| Q111291435 | SARS-CoV-2: Receptor and Co-receptor Tropism Probability |
| Q95603898 | Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins |
| Q108396537 | The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN |
Search more.